Loading
A phase 2 trial of Rocapuldencel-T run by Argos Therapeutics, terminated.
A Rollover Protocol for Subjects Previously Treated With AGS-003 is a phase 2 interventional study registered as NCT01482949 by Argos Therapeutics, with 2 participants enrolled, started 2011-09. Conditions recorded: Renal Cell Carcinoma. Interventions recorded: AGS-003.
Shares Rocapuldencel-T, Argos Therapeutics, Renal cell carcinoma and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics, Renal cell carcinoma and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics, Renal cell carcinoma and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics, Renal cell carcinoma and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/